Advancements in Cellular Immunotherapies in the Immune Checkpoint Inhibitor Era for Cancer Treatment

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1591

Special Issue Editors


E-Mail Website
Guest Editor
Programa Institucional de Fomento a la Investigación, Desarrollo e Innovación, Universidad Tecnológica Metropolitana, Santiago 8940577, Chile
Interests: connexin; immune response; tumor cells; cancer therapy; biomarkers; antitumor immunotherapies

E-Mail Website
Guest Editor
1. Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago 8380453, Chile
2. Millennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile
3. Department of Medicine Solna, Karolinska Institute, 17176 Stockholm, Sweden
Interests: tumor immunology; cancer immunotherapy; dendritic cells

Special Issue Information

Dear Colleagues,

The landscape of cancer treatment has undergone a remarkable transformation with the advent of immune checkpoint inhibitors (ICIs). These groundbreaking therapies have ushered in a new era in the fight against cancer by unleashing the power of the immune system to target and destroy malignant cells. Concurrently, cellular immunotherapies have emerged as a promising treatment frontier, offering personalized and precise approaches to combat this complex disease. Cell-mediated immunity can eliminate cancer cells and provide durable remissions. This Special Issue, entitled "Advancements in Cellular Immunotherapies in the Immune Checkpoint Inhibitor Era for Cancer Treatment," aims to provide a comprehensive overview of the latest developments in this dynamic field, including dendritic cell-based vaccines, whole-tumor-cell vaccines, and adoptive cell (T-cell, NK cell, or CAR-T cell) transfer.

Dr. Andrés Tittarelli
Dr. Flavio Salazar-Onfray
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • CAR-T cells
  • NK-cell immunotherapy
  • adoptive T-cell transfer
  • dendritic cell cancer vaccines
  • whole-tumor-cell vaccines

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2717 KiB  
Article
A Microfluidics Approach for Ovarian Cancer Immune Monitoring in an Outpatient Setting
by Sarah Libbrecht, Ann Vankerckhoven, Koen de Wijs, Thaïs Baert, Gitte Thirion, Katja Vandenbrande, Toon Van Gorp, Dirk Timmerman, An Coosemans and Liesbet Lagae
Cells 2024, 13(1), 7; https://doi.org/10.3390/cells13010007 - 20 Dec 2023
Viewed by 1418
Abstract
Among cancer diagnoses in women, ovarian cancer has the fifth-highest mortality rate. Current treatments are unsatisfactory, and new therapies are highly needed. Immunotherapies show great promise but have not reached their full potential in ovarian cancer patients. Implementation of an immune readout could [...] Read more.
Among cancer diagnoses in women, ovarian cancer has the fifth-highest mortality rate. Current treatments are unsatisfactory, and new therapies are highly needed. Immunotherapies show great promise but have not reached their full potential in ovarian cancer patients. Implementation of an immune readout could offer better guidance and development of immunotherapies. However, immune profiling is often performed using a flow cytometer, which is bulky, complex, and expensive. This equipment is centralized and operated by highly trained personnel, making it cumbersome and time-consuming. We aim to develop a disposable microfluidic chip capable of performing an immune readout with the sensitivity needed to guide diagnostic decision making as close as possible to the patient. As a proof of concept of the fluidics module of this concept, acquisition of a limited immune panel based on CD45, CD8, programmed cell death protein 1 (PD1), and a live/dead marker was compared to a conventional flow cytometer (BD FACSymphony). Based on a dataset of peripheral blood mononuclear cells of 15 patients with ovarian cancer across different stages of treatment, we obtained a 99% correlation coefficient for the detection of CD8+PD1+ T cells relative to the total amount of CD45+ white blood cells. Upon further system development comprising further miniaturization of optics, this microfluidics chip could enable immune monitoring in an outpatient setting, facilitating rapid acquisition of data without the need for highly trained staff. Full article
Show Figures

Figure 1

Back to TopTop